Breast cancer subtypes: implications for the treatment and survival of patients in Africa—a prospective cohort study from Mozambique. Issue 5 (5th October 2020)

• Record Type: Journal Article
• Authors: Brandão, Mariana; Guisseve, Assucena; Bata, Genoveva; Alberto, Matos; Ferro, Josefo; Garcia, Carlos; Zaqueu, Clésio; Lorenzoni, Cesaltina; Leitão, Dina; Come, Jotamo; Soares, Otília; Gudo-Morais, Alberto; Schmitt, Fernando; Tulsidás, Satish; Carrilho, Carla; Lunet, Nuno
• Is Part Of: ESMO open. Volume 5:Issue 5(2020)
• Publication Date: 2020-10-05
• Subjects: breast neoplasms -- biomarkers -- survival analysis -- sub-Saharan Africa -- global health; Cancer -- Periodicals; 616.994005
• DOI: 10.1136/esmoopen-2020-000829
• Languages: English
• ISSNs: 2059-7029

Abstract

Abstract : Background: Data regarding breast cancer epidemiology, treatment and survival in Africa are scarce. We aimed to assess the distribution of breast cancer subtypes in Mozambique and its impact on patients' treatment and survival. The concordance of biomarker assessment between cytological and histological samples was also evaluated. Methods: Prospective cohort study including 210 patients diagnosed between January 2015 and August 2017, followed to November 2019. Clinicopathological characteristics, treatment, 3-year overall survival (OS) and disease-free survival (DFS) were compared across classic tumour subtypes (oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative breast cancer (TNBC)) and surrogate intrinsic subtypes (St. Gallen classification). Concordance was measured using Cohen's κ statistics. Results: A total of 51% of patients had ER-positive/HER2-negative tumours, 24% HER2-positive and 25% TNBC. Concordance between cytological and histological samples regarding ER and HER2 status was substantial (κ=0.762 and κ=0.603, respectively). There were no significant differences across subtypes regarding clinical characteristics and treatment, except for HIV positivity and high histological grade (more prevalent among TNBC) or endocrine therapy (higher use among ER-positive/HER2-negative and HER2-positive patients). Three-year OS was 52.5% (95% CI, 44.3% to 60.0%), being higher in ER-positive/HER2-negative (61.1%) compared with HER2-positive (53.2%) and TNBC (31.9%) patients. Adjusted HRs were 1.96 (95% CI, 1.13 to 3.39) among HER2-positive and 3.10 (95% CI, 1.81 to 5.31) among TNBC versus ER-positive/HER2-negative patients. Three-year DFS was 46.6% (95% CI, 38.0% to 54.8%), being lower among TNBC versus ER-positive/HER2-negative patients (HR 2.91; 95% CI, 1.64 to 5.16). Results were similar between surrogate intrinsic subtypes. Conclusion: There was a high proportion of HER2-positive and TNBC among Mozambican patients and their survival was poor compared with ER-positive/HER2-negative patients, partly due to the limited treatment options. A systematic assessment of ER, PR and HER2 status is feasible and may help tailoring and optimise the treatment of patients with breast cancer in low-resource settings, potentially leading to survival gains in this underserved population.